The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
The first human glucagon-like peptide-1 analog (liraglutide) was registered in Russia in May 2010. This review contains data on the results of randomizedclinical studies of this preparation applied to the treatment of patients with DM2 as monotherapy and in combination with traditional hypoglycemica...
Guardado en:
Autor principal: | Marina Vladimirovna Shestakova |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e55f297af3a34572a8a0d9d97b6af3d0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
por: Gagik R. Galstyan, et al.
Publicado: (2017) -
Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
por: Nina A. Petunina, et al.
Publicado: (2018) -
First GLP-1 analog liraglutide: the result of clinical trails on efficacy
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011) -
The associations of incretin hormone concentration with gestational diabetes mellitus
por: Tatiana V. Saprina, et al.
Publicado: (2016) -
Nephroprotective potential of glucagon-like peptide-1 receptor agonists
por: Minara S. Shamkhalova, et al.
Publicado: (2020)